CG Oncology (CGON) Accumulated Expenses (2023 - 2026)

CG Oncology's Accumulated Expenses history runs 4 years deep, the most recent figure standing at $25.9 million for Q1 2026.

• Quarterly Accumulated Expenses rose 65.52% year-over-year to $25.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.9 million (up 65.52% YoY) and the FY2025 annual result came in at $24.2 million, up 65.07% from the prior year.
• Accumulated Expenses was $25.9 million for Q1 2026 at CG Oncology, up from $24.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $25.9 million in Q1 2026 and bottomed at $5.1 million in Q1 2024.
• A 4-year average of $15.8 million and a median of $15.2 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 40.43% — and 2025, when it jumped 222.36%.
• CG Oncology's Accumulated Expenses stood at $10.4 million in 2023, then jumped by 40.43% to $14.7 million in 2024, then soared by 65.07% to $24.2 million in 2025, then grew by 7.05% to $25.9 million in 2026.
• Business Quant data shows CGON's Accumulated Expenses at $25.9 million in Q1 2026, $24.2 million in Q4 2025, and $20.4 million in Q3 2025.